New stock news | Mingyu Pharmaceutical submits application to Hong Kong Stock Exchange again
According to the Hong Kong Stock Exchange's disclosure on July 8th, Miric Pharmaceutical Limited-B (referred to as Miric Pharmaceuticals) has once again submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities serving as its joint sponsors.
According to the disclosure by Hong Kong Stock Exchange on July 8, Mingyu Pharmaceutical Limited-B (referred to as Mingyu Pharmaceutical) has once again submitted its listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as its joint sponsors. According to the prospectus, the company was established in 2018 and is a biotechnology company focusing on integrated oncology, with a research focus on the development of Antibody-Drug Conjugates (ADC) and advanced immunotherapy. As of the latest practicable date (July 1, 2026), the company's research pipeline includes 11 candidate products, including two core products.
Related Articles
.png)
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.
GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.
GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
RECOMMEND
